Global News

Citeline adds service for site identification in China

Wednesday, January 7, 2015 12:54 PM

Citeline, an Informa business unit, has released Chinatrove, the newest addition to its suite of pharma R&D intelligence services.

More... »


Date set for arbitration trial between CEL-SCI and inVentiv

Wednesday, January 7, 2015 12:45 PM

CEL-SCI, a biotechnology company based in Vienna, Va., has announced that the trial in its ongoing arbitration against CRO inVentiv Clinical currently is scheduled for May 4.

More... »


Gilead Sciences acquires Phenex Pharmaceuticals’ NASH development program

Wednesday, January 7, 2015 12:42 PM

Gilead Sciences, a biopharmaceutical company headquartered in Foster City, Calif., and Phenex Pharmaceuticals, a privately held German biotechnology company, have signed a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH). Gilead will pay Phenex an upfront payment plus additional payments based upon achievement of certain development milestones that may potentially be worth up to $470 million.

More... »

Intellia Therapeutics, Novartis partner

Wednesday, January 7, 2015 12:40 PM

Intellia Therapeutics, a Cambridge, Mass.-based developer of therapeutic products using CRISPR/Cas9 technology for gene editing and repair, has announced a five-year R&D collaboration with Novartis to accelerate the ex vivo development of new CRISPR/Cas9-based therapies using chimeric antigen receptor T cells (CARTs) and hematopoetic stem cells (HSCs).

More... »

Pfizer acquires Redvax

Tuesday, January 6, 2015 09:00 AM

Pfizer has acquired a controlling interest in Redvax, a spinoff from Redbiotec, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.

More... »

Mapi completes acquisition of Optum Life Sciences services

Tuesday, January 6, 2015 08:00 AM

Mapi, a global health research and commercialization services company, has completed the acquisition of select Optum Life Sciences services, including North American and European Regulatory Consulting, Late Phase CRO and European Health Economics and Outcomes Research (HEOR) teams.

More... »

U.S. immunity against legal claims given to developers of Ebola treatments

Monday, January 5, 2015 12:52 PM

Health and Human Services Secretary Sylvia M. Burwell has announced a declaration under the Public Readiness and Emergency Preparedness (PREP) Act to facilitate the development and availability of experimental Ebola vaccines. This declaration is intended to assist in the global community's effort to help combat the current epidemic in West Africa and help prevent future outbreaks there.

More... »

UPS to acquire Polish healthcare logistics company Poltraf

Monday, January 5, 2015 12:51 PM

UPS has agreed to terms with Poland-based investment fund ORTIE to acquire its pharmaceutical logistics company Poltraf. The acquisition will further strengthen UPS' healthcare experience and network in Europe, enabling compliant logistics services to customers for streamlining their product supply to the fast-growing healthcare markets of Central and Eastern Europe.

More... »

Sevion, Johnson & Johnson Innovation, Janssen collaborate for antibody discovery

Monday, January 5, 2015 12:40 PM

Sevion Therapeutics, which discovers, develops and acquires next-generation biologics, is collaborating with CNA Development, an affiliate of Janssen Pharmaceuticals, to discover antibodies using Sevion's spatially addressed library platform.

More... »

Lilly inks diabetes research partnership with University of Surrey

Monday, January 5, 2015 12:39 PM

Eli Lilly has announced a five-year research partnership with U.K.-based University of Surrey to study health outcomes, focusing on the effects of treatment in people with type 2 diabetes, which affect about 95% of those with the disease.

More... »

`
CenterWatch Data Library
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs